PubMed Health⌕ Search

Biomedical subjects

M Crofts

Publications and source records attributed to M Crofts.

6 recordsLinked to original sources
PubMed1987

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.

A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the 51CR EDTA absorption test, a new method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan. The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which resulted from high dose melphalan.

Adult↗
PubMed1985

Myelodysplastic syndrome or acute myeloid leukemia? A study of 28 cases presenting with borderline features.

Some patients present borderline features between acute myeloid leukemia (AML) and typical myelodysplastic syndromes (MDS): an excess of blasts insufficient to conclusively diagnose AML, yet above the figures usually compatible with MDS or the presence of Auer rods associated with a moderate excess of blasts. This presents considerable difficulties in diagnosis and management. The authors studied 28 such cases using the French-American-British Co-operative Group (FAB) classification, which groups them into a separate category termed "refractory anemia with excess of blasts in transformation" (RAEB-T). This was found to be a heterogenous group. Certain patients (4/28) had a previously established myelodysplasia, but most presented directly as RAEB-T. Two very different pictures emerged: a few patients (4/28) were young, with presentation and evolution similar to classic AML, for whom combination chemotherapy was effective; the majority (20/28) were older, with more varied clinical and cytologic presentation, for whom chemotherapy was of little effect and who presented a picture resembling classic RAEB with a median survival of 10 months.

Adolescent↗
PubMed1984

Cyclosporine--a model for the testing of bio-immunological reaction modifiers in man.

Cyclosporine is a member of a new family of drugs which interfere and modify the biological regulation of the immune system without being cytotoxic and has now been tested extensively in man. Observation of its toxicity in a homogeneous group of 72 patients with acute myeloblastic leukaemia receiving bone marrow transplants serves to illustrate some of the new and unexpected problems that may be seen when BIRM agents start to be tested in the clinic.

Adolescent↗